These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 25624301)

  • 21. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Petridis I; Tavridou A; Christakidis D; Manolopoulos VG
    Pharmacogenomics; 2009 Nov; 10(11):1781-7. PubMed ID: 19891554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): good for sulfonylureas?
    Al-Ozairi E; Sibal L; Home P
    Diabetes Care; 2007 Jun; 30(6):1677-80. PubMed ID: 17351288
    [No Abstract]   [Full Text] [Related]  

  • 23. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes.
    Charbonnel B
    Int J Clin Pract Suppl; 2007 Jun; (153):1-2. PubMed ID: 17594387
    [No Abstract]   [Full Text] [Related]  

  • 24. [Proton pump inhibitors are suspected of serious adverse effects. More cautious prescribing should be considered and on correct indications].
    Backman L; Schmidt D; Vitols S
    Lakartidningen; 2013 Apr 17-23; 110(16):828-31. PubMed ID: 23717929
    [No Abstract]   [Full Text] [Related]  

  • 25. [Pharmacodynamics of second generation sulfonylureas: dose-effect curve of gliclazide in type 2 diabetes mellitus].
    Procacci V; Giovine A; Roberto MG; Di Reda N; Lasorsa G; Vendemiale G; Stufano N; Altomare E
    Boll Soc Ital Biol Sper; 1988 Sep; 64(9):817-24. PubMed ID: 3072977
    [No Abstract]   [Full Text] [Related]  

  • 26. Oral sulfonylureas and CV mortality.
    Aronow WS
    Geriatrics; 2004 Sep; 59(9):45-6, 49. PubMed ID: 15461238
    [No Abstract]   [Full Text] [Related]  

  • 27. Pareto's law and sulfonylureas.
    Peiris AN; Micklewright M; Gangadharan V
    South Med J; 2007 Nov; 100(11):1072-3. PubMed ID: 17984734
    [No Abstract]   [Full Text] [Related]  

  • 28. Sulfonylurea use is associated with larger infarct size in patients with diabetes and ST-elevation myocardial infarction.
    Abdelmoneim AS; Welsh RC; Eurich DT; Simpson SH
    Int J Cardiol; 2016 Jan; 202():126-30. PubMed ID: 26386939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Sulfonylureas].
    Kobayashi K; Shimano H
    Nihon Rinsho; 2012 May; 70 Suppl 3():602-7. PubMed ID: 22768585
    [No Abstract]   [Full Text] [Related]  

  • 30. Pioglitazone with sulfonylurea: glycemic and lipid effects in Taiwanese type 2 diabetic patients.
    Tseng CH; Huang TS
    Diabetes Res Clin Pract; 2005 Nov; 70(2):193-4. PubMed ID: 16188579
    [No Abstract]   [Full Text] [Related]  

  • 31. Failure of sulfonylureas in type 2 diabetes.
    Yildiz BO; Gürlek A
    Horm Metab Res; 1999 Apr; 31(4):293-4. PubMed ID: 10333089
    [No Abstract]   [Full Text] [Related]  

  • 32. If not sulfonylureas, then what?
    Leibovitch ER
    Geriatrics; 2004 Sep; 59(9):47-8. PubMed ID: 15461239
    [No Abstract]   [Full Text] [Related]  

  • 33. Use oral hypoglycemics with caution..
    Jackson JE; Bressler R
    Geriatrics; 1988 Aug; 43(8):77-83. PubMed ID: 3136057
    [No Abstract]   [Full Text] [Related]  

  • 34. Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study.
    Berkowitz SA; Krumme AA; Avorn J; Brennan T; Matlin OS; Spettell CM; Pezalla EJ; Brill G; Shrank WH; Choudhry NK
    JAMA Intern Med; 2014 Dec; 174(12):1955-62. PubMed ID: 25347323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beyond sulfonylureas: new oral medications in the treatment of NIDDM (type II DM).
    Capriotti T
    Medsurg Nurs; 1997 Jun; 6(3):166-9. PubMed ID: 9238992
    [No Abstract]   [Full Text] [Related]  

  • 36. Late complications of diabetes mellitus: risk factors in patients on sulfonylureas for more than 10 years.
    Hoshi M; Fujita S
    Jpn J Med; 1991; 30(6):616-7. PubMed ID: 1798228
    [No Abstract]   [Full Text] [Related]  

  • 37. Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
    Mühlhauser I; Sawicki PT; Berger M
    Diabetologia; 1997 Dec; 40(12):1492-3. PubMed ID: 9447960
    [No Abstract]   [Full Text] [Related]  

  • 38. [Glipizide treatment does not change erythrocyte insulin receptors in non-insulin-dependent diabetics].
    Canivet B; Freychet P
    Therapie; 1985; 40(2):93-7. PubMed ID: 4002196
    [No Abstract]   [Full Text] [Related]  

  • 39. Potential impact of sulfonylureas in the outcome of type 2 diabetic patients with ischemic stroke.
    Arboix A
    Stroke; 2007 Sep; 38(9):2413-4. PubMed ID: 17673799
    [No Abstract]   [Full Text] [Related]  

  • 40. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.
    Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH
    Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.